{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:05:46Z","timestamp":1792868746208,"version":"4.5.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T00:00:00Z","timestamp":1549065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R56HL141466"],"award-info":[{"award-number":["R56HL141466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1093\/cvr\/cvz026","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:32:01Z","timestamp":1548376321000},"page":"854-868","source":"Crossref","is-referenced-by-count":459,"title":["Cardiovascular toxicities associated with immune checkpoint inhibitors"],"prefix":"10.1093","volume":"115","author":[{"given":"Jiun-Ruey","family":"Hu","sequence":"first","affiliation":[{"name":"Division of Cardiology, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Florido","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Lipson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA"},{"name":"Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Ardehali","sequence":"additional","affiliation":[{"name":"Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, 675 Charles E Young Dr S, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Via Pansini 5, Naples, NA, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R","family":"Lyon","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Service, Royal Brompton Hospital, Dovehouse St, London, UK"},{"name":"National Heart and Lung Institute, Imperial College London, Sydney Street, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Padera","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, 75 Francis St, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,2]]},"reference":[{"key":"2019051603104866000_cvz026-B1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"2019051603104866000_cvz026-B2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2019051603104866000_cvz026-B3","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"2019051603104866000_cvz026-B4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"2019051603104866000_cvz026-B5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"2019051603104866000_cvz026-B6","doi-asserted-by":"crossref","first-page":"4.","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome","volume":"3","author":"Geisler","year":"2015","journal-title":"J ImmunoTher Cancer"},{"key":"2019051603104866000_cvz026-B7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2019051603104866000_cvz026-B8","doi-asserted-by":"crossref","first-page":"11.","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J ImmunoTher Cancer"},{"key":"2019051603104866000_cvz026-B9","first-page":"794842","author":"Yun","year":"2015"},{"key":"2019051603104866000_cvz026-B10","doi-asserted-by":"crossref","DOI":"10.1201\/9781315533247","volume-title":"Janeway\u2019s Immunobiology","author":"Murphy","year":"2016","edition":"9th ed"},{"key":"2019051603104866000_cvz026-B11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/713774061","article-title":"Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells","volume":"9","author":"Eppihimer","year":"2002","journal-title":"UMIC"},{"key":"2019051603104866000_cvz026-B12","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019051603104866000_cvz026-B13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"2019051603104866000_cvz026-B14","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1093\/cvr\/cvy160","article-title":"Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases","volume":"114","author":"Mehta","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2019051603104866000_cvz026-B15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"2019051603104866000_cvz026-B16","doi-asserted-by":"crossref","first-page":"15440.","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat Commun"},{"key":"2019051603104866000_cvz026-B17","volume-title":"Hematology\/Oncology (Cancer) Approvals & Safety Notifications","year":"2018"},{"key":"2019051603104866000_cvz026-B18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2019051603104866000_cvz026-B19","doi-asserted-by":"crossref","first-page":"e58006.","DOI":"10.1371\/journal.pone.0058006","article-title":"Tim-3 expression defines regulatory T cells in human tumors","volume":"8","author":"Yan","year":"2013","journal-title":"PLoS One"},{"key":"2019051603104866000_cvz026-B20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"2019051603104866000_cvz026-B21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"2019051603104866000_cvz026-B22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ni944","article-title":"BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1","volume":"4","author":"Watanabe","year":"2003","journal-title":"Nat Immunol"},{"key":"2019051603104866000_cvz026-B23","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"2019051603104866000_cvz026-B24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2019051603104866000_cvz026-B25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ijcard.2016.07.291","article-title":"Apical takotsubo syndrome in a patient with metastatic breast carcinoma on novel immunotherapy","volume":"222","author":"Anderson","year":"2016","journal-title":"Int J Cardiol"},{"key":"2019051603104866000_cvz026-B26","doi-asserted-by":"crossref","first-page":"50.","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J ImmunoTher Cancer"},{"key":"2019051603104866000_cvz026-B27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-Like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2019051603104866000_cvz026-B28","doi-asserted-by":"crossref","first-page":"e1925","DOI":"10.1097\/MJT.0000000000000430","article-title":"Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma","volume":"23","author":"Roth","year":"2016","journal-title":"Am J Ther"},{"key":"2019051603104866000_cvz026-B29","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"U.S. Food and Drug Administration approval summary: atezolizumab for metastatic non\u2013small cell lung cancer","volume":"23","author":"Weinstock","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2019051603104866000_cvz026-B30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5114\/amsad.2017.72531","article-title":"A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) \u2013 systemic inflammatory response syndrome after use of pembrolizumab","volume":"2","author":"Nykl","year":"2017","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"2019051603104866000_cvz026-B31","doi-asserted-by":"crossref","first-page":"155.","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"key":"2019051603104866000_cvz026-B32","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","volume":"2016","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2019051603104866000_cvz026-B33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2019051603104866000_cvz026-B34","doi-asserted-by":"crossref","first-page":"933.","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2019051603104866000_cvz026-B35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"2019051603104866000_cvz026-B36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","article-title":"PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes","volume":"13","author":"Du","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2019051603104866000_cvz026-B37","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"2019051603104866000_cvz026-B38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"2019051603104866000_cvz026-B39","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2019051603104866000_cvz026-B40","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"2019051603104866000_cvz026-B41","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"Cardiovascular magnetic resonance in myocarditis: a JACC white paper","volume":"53","author":"Friedrich","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2019051603104866000_cvz026-B42","doi-asserted-by":"crossref","first-page":"e0178607","DOI":"10.1371\/journal.pone.0178607","article-title":"Plasma brain natriuretic peptide levels are elevated in patients with cancer","volume":"12","author":"Bando","year":"2017","journal-title":"PLoS One"},{"key":"2019051603104866000_cvz026-B43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2014-206812","article-title":"Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity","volume":"74","author":"Hughes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2019051603104866000_cvz026-B44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","article-title":"Update on myocarditis","volume":"59","author":"Kindermann","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2019051603104866000_cvz026-B45","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0025-6196(12)61286-5","article-title":"Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error","volume":"64","author":"Hauck","year":"1989","journal-title":"Mayo Clin Proc"},{"key":"2019051603104866000_cvz026-B46","year":"2017"},{"key":"2019051603104866000_cvz026-B47","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"2019051603104866000_cvz026-B48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal complications of immune checkpoint inhibitors","volume":"14","author":"Sury","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2019051603104866000_cvz026-B49","doi-asserted-by":"crossref","first-page":"10391.","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"2019051603104866000_cvz026-B50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cardiores.2005.01.011","article-title":"Healing after myocardial infarction","volume":"66","author":"Ertl","year":"2005","journal-title":"Cardiovasc Res"},{"key":"2019051603104866000_cvz026-B51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"2019051603104866000_cvz026-B52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"2019051603104866000_cvz026-B53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cardiores.2007.03.012","article-title":"Roles of programmed death-1 (PD-1)\/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3","volume":"75","author":"Seko","year":"2007","journal-title":"Cardiovasc Res"},{"key":"2019051603104866000_cvz026-B54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"2019051603104866000_cvz026-B55","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"2019051603104866000_cvz026-B56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cvr\/cvz025","article-title":"T cell checkpoint regulators in the heart","volume":"115","author":"Grabie","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2019051603104866000_cvz026-B57","doi-asserted-by":"crossref","first-page":"e0124059.","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153","volume":"10","author":"Baban","year":"2015","journal-title":"PLoS One"},{"key":"2019051603104866000_cvz026-B58","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cvr\/cvx248","article-title":"Exploring immune checkpoints as potential therapeutic targets in atherosclerosis","volume":"114","author":"Kusters","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2019051603104866000_cvz026-B59","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2019051603104866000_cvz026-B60","doi-asserted-by":"crossref","first-page":"807.","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"2019051603104866000_cvz026-B61","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy","volume":"117","author":"Tay","year":"2017","journal-title":"Br J Cancer"},{"key":"2019051603104866000_cvz026-B62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CJI.0000000000000217","article-title":"Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy","volume":"41","author":"Almeida","year":"2018","journal-title":"J Immunother"},{"key":"2019051603104866000_cvz026-B63","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijcard.2016.08.023","article-title":"Pericardial effusion with tamponade physiology induced by nivolumab","volume":"222","author":"Nesfeder","year":"2016","journal-title":"Int J Cardiol"},{"key":"2019051603104866000_cvz026-B64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature","volume":"7","author":"Shaheen","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"2019051603104866000_cvz026-B65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000447053","article-title":"Nivolumab-induced pericardial tamponade: a case report and discussion","volume":"136","author":"Kushnir","year":"2017","journal-title":"Cardiology"},{"key":"2019051603104866000_cvz026-B66","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"2019051603104866000_cvz026-B67","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019051603104866000_cvz026-B68","doi-asserted-by":"crossref","first-page":"41.","DOI":"10.1186\/s40425-014-0041-1","article-title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","volume":"2","author":"Manusow","year":"2014","journal-title":"J ImmunoTher Cancer"},{"key":"2019051603104866000_cvz026-B69","doi-asserted-by":"crossref","first-page":"12.","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","volume":"6","author":"Padda","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"2019051603104866000_cvz026-B70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"2019051603104866000_cvz026-B71","article-title":"Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy","volume":"2017","author":"Roy","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2019051603104866000_cvz026-B72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0897190017699762","article-title":"Case report of ipilimumab-induced diffuse, nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis","volume":"31","author":"Arellano","year":"2018","journal-title":"J Pharm Pract"},{"key":"2019051603104866000_cvz026-B73","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"Brom","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2019051603104866000_cvz026-B74","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2019051603104866000_cvz026-B75","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"2019051603104866000_cvz026-B76","doi-asserted-by":"crossref","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","author":"Watanabe","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2019051603104866000_cvz026-B77","doi-asserted-by":"crossref","first-page":"E970","DOI":"10.1073\/pnas.1616848114","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019051603104866000_cvz026-B78","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S1470-2045(18)30622-3","article-title":"Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors","volume":"19","author":"Varricchi","year":"2018","journal-title":"Lancet Oncol"},{"key":"2019051603104866000_cvz026-B79","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","article-title":"BSR and BHPR guidelines for the management of giant cell arteritis","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2019051603104866000_cvz026-B80","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2019051603104866000_cvz026-B81","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The immune checkpoint inhibitors: where are we now?","volume":"13","author":"Webster","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2019051603104866000_cvz026-B82","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac toxicity in patients treated with immune checkpoint inhibitors","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/115\/5\/854\/28652041\/cvz026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T17:23:48Z","timestamp":1606152228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/115\/5\/854\/5304411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,2]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,2]]},"published-print":{"date-parts":[[2019,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvz026","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,15]]},"published":{"date-parts":[[2019,2,2]]}}}